Search Back New search Go to resultsDiseaseMain groupSolid TumorsProtocol groupGynecological OncologyUrologic OncologyDiseaseOsteoporosisSubgroupICD10M80.-M80.0-M80.4-M81.-M81.0-M81.4-MeSHOsteoporosisSequenceChemotherapyChemo-substanceChemo-substanceChemo-substanceChemo-substanceNo. Substances RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionZoledronic AcidSupportive substanceBalanced Crystalloid SolutionZoledronic AcidSupportive substanceBalanced Crystalloid SolutionZoledronic AcidSupportive substanceBalanced Crystalloid SolutionZoledronic AcidNo. Substances2Protocol classificationTherapy classificationcurrent standardIntensityStandard doseTherapy indicationTherapy phaseTherapy intentionsupportiveRisksAnemia Hb below 8g/dlArthalgiaBone PainCardiotoxicityHeadacheMyalgiasNauseaPyrexiaRenal Failure only studiesPublicationAuthorBlack DDiseaseOsteoporose bei Frauen postmenopausal, Alter 65-89, T-score -2,5OriginUniversity of California, San Francisco, San Francisco, HORIZON Pivotal Fracture TrialProtocols in Revision 2 protocols foundProtocols under revision.Zoledronate 4, Osteoporosis (PID1392 V1.0)Zoledronate 5, Osteoporosis (PID1393 V1.0)
